Harnessing A Diverse Collection Of CRISPR-Associated RNA-Guided Nucleases For Precise Gene Editing

Life Edit is advancing the field of genomic medicine with its proprietary CRISPR technologies and delivery systems, enabling precise gene editing across a broad range of therapeutic applications. The company utilizes Type II and Type V RNA-guided nucleases, supported by an extensive library of over 2 million CRISPR-Cas systems with diverse PAM sequences, offering highly specific and efficient gene editing capabilities. These systems enable editing modalities such as knock-out, insertion/repair, base editing, and reverse transcriptase editing.

Life Edit’s innovations include the LETI-101 approach for Huntington's disease, which uses a compact CRISPR system delivered via AAV5 for targeted allele-specific editing of the mutant HTT gene, potentially offering a one-time treatment. Additionally, the proprietary LNP platform enables efficient, low-immunogenicity delivery, while base editing systems allow for precise genetic corrections. Life Edit employs a comprehensive strategy to assess off-target effects, ensuring high editing specificity. To learn more about Life Edit’s groundbreaking approach, access the full presentation below.